Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173, Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea.
Institute of Health and Environment, Seoul National University, Seoul, South Korea.
Sci Rep. 2024 Feb 11;14(1):3449. doi: 10.1038/s41598-024-53837-z.
In this study, we investigated the characteristics of gut microbiome in the metabolically healthy obese (MHO) patients, and how they correlate with metabolic and inflammatory profiles. A total of 120 obese people without metabolic comorbidities were recruited, and their clinical phenotypes, metabolic and inflammatory parameters were analysed. The faecal microbial markers originating from bacterial cell and extracellular vesicle (EV) were profiled using 16S rDNA sequencing. The total study population could be classified into two distinct enterotypes (enterotype I: Prevotellaceae-predominant, enterotype II: Akkermansia/Bacteroides-predominant), based on their stool EV-derived microbiome profile. When comparing the metabolic and inflammatory profiles, subjects in enterotype I had higher levels of serum IL-1β [false discovery rate (FDR) q = 0.050] and had a lower level of microbial diversity than enterotype II (Wilcoxon rank-sum test p < 0.01). Subjects in enterotype I had relatively higher abundance of Bacteroidetes, Prevotellaceae and Prevotella-derived EVs, and lower abundance of Actinobacteria, Firmicutes, Proteobacteria, Akkermansia and Bacteroides-derived EVs (FDR q < 0.05). In conclusion, HMO patients can be categorised into two distinct enterotypes by the faecal EV-derived microbiome profile. The enterotyping may be associated with different metabolic and inflammatory profiles. Further studies are warranted to elucidate the long-term prognostic impact of EV-derived microbiome in the obese population.
在这项研究中,我们研究了代谢健康肥胖(MHO)患者肠道微生物组的特征,以及它们与代谢和炎症特征的相关性。共招募了 120 名无代谢合并症的肥胖患者,分析了他们的临床表型、代谢和炎症参数。使用 16S rDNA 测序对源自细菌细胞和细胞外囊泡(EV)的粪便微生物标志物进行了分析。根据粪便 EV 衍生微生物组的特征,可将整个研究人群分为两种不同的肠型(肠型 I:普雷沃氏菌科为主,肠型 II:阿克曼氏菌/拟杆菌为主)。当比较代谢和炎症特征时,肠型 I 组的血清 IL-1β 水平更高[错误发现率(FDR)q=0.050],且微生物多样性水平低于肠型 II 组(Wilcoxon 秩和检验,p<0.01)。肠型 I 组的拟杆菌门、普雷沃氏菌科和普雷沃氏菌衍生 EVs 的相对丰度较高,而放线菌门、厚壁菌门、变形菌门、阿克曼氏菌和拟杆菌衍生 EVs 的相对丰度较低(FDR q<0.05)。总之,HMO 患者可根据粪便 EV 衍生微生物组特征分为两种不同的肠型。这种肠型可能与不同的代谢和炎症特征相关。需要进一步的研究来阐明肥胖人群中 EV 衍生微生物组的长期预后影响。